Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
View post:
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce that its preclinical data on optic nerve regeneration study was presented today at the Annual Meeting of the Association for Research in Vision and Ophthalmology (“ARVO) in Salt Lake City Utah, the world's largest and most respected vision science conference.
Read the original post:
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO)...
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:
Go here to see the original:
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025
Read the rest here:
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025.
The rest is here:
SIGA Reports Financial Results for Three Months Ended March 31, 2025
Q1 Revenue of $6.3 million, growth year over year of 24%
View original post here:
Senseonics Holdings, Inc. Reports First Quarter Financial Results
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025.
View post:
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025
Go here to see the original:
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2025 and provided a business update.
View post:
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date
See the rest here:
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update